{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:10:17Z","timestamp":1793337017617,"version":"4.5.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR001882"],"award-info":[{"award-number":["KL2TR001882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03352-y","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:45:29Z","timestamp":1757058329000},"page":"5341-5364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization"],"prefix":"10.1007","volume":"42","author":[{"given":"Vidhi","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-4443","authenticated-orcid":false,"given":"Amanda","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"3352_CR1","unstructured":"World Health Organization: Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025). Accessed July 20, 2025."},{"key":"3352_CR2","unstructured":"World Obesity Federation. World Obesity Atlas 2023. 2023."},{"key":"3352_CR3","doi-asserted-by":"crossref","unstructured":"Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021\u2013August 2023. National Health and Nutrition Examination Survey: National Center for Health Statistics; 2024.","DOI":"10.15620\/cdc\/159281"},{"issue":"1","key":"3352_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-019-1449-8","volume":"17","author":"DM Cesare","year":"2019","unstructured":"Cesare DM, Sori\u0107 M, Bovet P, Miranda JJ, Bhutta Z, Stevens AG, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med. 2019;17(1):212. https:\/\/doi.org\/10.1186\/s12916-019-1449-8.","journal-title":"BMC Med"},{"issue":"2","key":"3352_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1210\/er.2017-00253","volume":"39","author":"AG Bray","year":"2018","unstructured":"Bray AG, Heisel EW, Afshin A, Jensen DM, Dietz HW, Long M, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39(2):79\u2013132. https:\/\/doi.org\/10.1210\/er.2017-00253.","journal-title":"Endocr Rev"},{"issue":"6","key":"3352_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ijo.2008.11","volume":"32","author":"A Romero-Corral","year":"2008","unstructured":"Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes. 2008;32(6):959\u201366. https:\/\/doi.org\/10.1038\/ijo.2008.11.","journal-title":"Int J Obes"},{"issue":"5","key":"3352_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/ijo.2016.17","volume":"40","author":"AJ Tomiyama","year":"2016","unstructured":"Tomiyama AJ, Hunger JM, Nguyen-Cuu J, Wells C. Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005\u20132012. Int J Obes. 2016;40(5):883\u20136. https:\/\/doi.org\/10.1038\/ijo.2016.17.","journal-title":"Int J Obes"},{"issue":"16","key":"3352_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2024.20115","volume":"332","author":"K Schweitzer","year":"2024","unstructured":"Schweitzer K. Could the body roundness index one day replace the BMI? JAMA. 2024;332(16):1317\u20138. https:\/\/doi.org\/10.1001\/jama.2024.20115.","journal-title":"JAMA"},{"key":"3352_CR9","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.2337\/dc24-S008","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2023","unstructured":"American Diabetes Association Professional Practice C. 8. Obesity and weight management for the prevention and treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20132024. Diabetes Care. 2023;47:S145\u201357. https:\/\/doi.org\/10.2337\/dc24-S008.","journal-title":"Diabetes Care"},{"issue":"3","key":"3352_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/ajcn\/81.3.555","volume":"81","author":"Y Wang","year":"2005","unstructured":"Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81(3):555\u201363. https:\/\/doi.org\/10.1093\/ajcn\/81.3.555.","journal-title":"Am J Clin Nutr"},{"issue":"21","key":"3352_CR11","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/cir.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despr\u00e9s J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984\u20131010. https:\/\/doi.org\/10.1161\/cir.0000000000000973.","journal-title":"Circulation"},{"issue":"4","key":"3352_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/hypertensionaha.108.110320","volume":"53","author":"P Mathieu","year":"2009","unstructured":"Mathieu P, Poirier P, Pibarot P, Lemieux I, Despr\u00e9S J-P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension. 2009;53(4):577\u201384. https:\/\/doi.org\/10.1161\/hypertensionaha.108.110320.","journal-title":"Hypertension"},{"issue":"8","key":"3352_CR13","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/nu13082493","volume":"13","author":"CJ Holmes","year":"2021","unstructured":"Holmes CJ, Racette SB. The utility of body composition assessment in nutrition and clinical practice: an overview of current methodology. Nutrients. 2021;13(8):2493. https:\/\/doi.org\/10.3390\/nu13082493.","journal-title":"Nutrients"},{"issue":"3","key":"3352_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3352_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ecl.2016.04.004","volume":"45","author":"TK Kyle","year":"2016","unstructured":"Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45(3):511\u201320. https:\/\/doi.org\/10.1016\/j.ecl.2016.04.004.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"3352_CR16","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2020","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2020;320(3):C375\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"3352_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12967-019-1919-y","volume":"17","author":"A De Lorenzo","year":"2019","unstructured":"De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 2019;17(1):169. https:\/\/doi.org\/10.1186\/s12967-019-1919-y.","journal-title":"J Transl Med"},{"issue":"3","key":"3352_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1152\/physrev.00002.2024","volume":"105","author":"BE Levin","year":"2025","unstructured":"Levin BE, Geary N, Lutz TA. The (dys)regulation of energy storage in obesity. Physiol Rev. 2025;105(3):803\u201395. https:\/\/doi.org\/10.1152\/physrev.00002.2024.","journal-title":"Physiol Rev"},{"issue":"2","key":"3352_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","volume":"23","author":"RJF Loos","year":"2022","unstructured":"Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120\u201333. https:\/\/doi.org\/10.1038\/s41576-021-00414-z.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"3352_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/a:1025635913927","volume":"27","author":"HHM Maes","year":"1997","unstructured":"Maes HHM, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27(4):325\u201351. https:\/\/doi.org\/10.1023\/a:1025635913927.","journal-title":"Behav Genet"},{"issue":"2","key":"3352_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41380-024-02737-9","volume":"30","author":"S Saeed","year":"2024","unstructured":"Saeed S, Bonnefond A, Froguel P. Obesity: exploring its connection to brain function through genetic and genomic perspectives. Mol Psychiatry. 2024;30(2):651\u20138. https:\/\/doi.org\/10.1038\/s41380-024-02737-9.","journal-title":"Mol Psychiatry"},{"issue":"7538","key":"3352_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature14177","volume":"518","author":"AE Locke","year":"2015","unstructured":"Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197\u2013206. https:\/\/doi.org\/10.1038\/nature14177.","journal-title":"Nature"},{"issue":"2","key":"3352_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41366-019-0428-7","volume":"44","author":"FK Ndiaye","year":"2020","unstructured":"Ndiaye FK, Huyvaert M, Ortalli A, Canouil M, Lecoeur C, Verbanck M, et al. The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward. Int J Obes. 2020;44(2):539\u201343. https:\/\/doi.org\/10.1038\/s41366-019-0428-7.","journal-title":"Int J Obes"},{"issue":"S1","key":"3352_CR24","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/ijo.2010.184","volume":"34","author":"M Rosenbaum","year":"2010","unstructured":"Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010;34(S1):S47\u201355. https:\/\/doi.org\/10.1038\/ijo.2010.184.","journal-title":"Int J Obes"},{"key":"3352_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.physbeh.2013.07.009","volume":"120","author":"CN Ochner","year":"2013","unstructured":"Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav. 2013;120:106\u201313. https:\/\/doi.org\/10.1016\/j.physbeh.2013.07.009.","journal-title":"Physiol Behav"},{"issue":"4","key":"3352_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/s2213-8587(15)00009-1","volume":"3","author":"CN Ochner","year":"2015","unstructured":"Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet Diabetes Endocrinol. 2015;3(4):232\u20134. https:\/\/doi.org\/10.1016\/s2213-8587(15)00009-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3352_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/oby.23336","volume":"30","author":"Z Javed","year":"2022","unstructured":"Javed Z, Valero-Elizondo J, Maqsood MH, Mahajan S, Taha MB, Patel KV, et al. Social determinants of health and obesity: findings from a national study of US adults. Endocrinol Metab Clin North Am. 2022;30(2):491\u2013502. https:\/\/doi.org\/10.1002\/oby.23336.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3352_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pcad.2023.04.011","volume":"78","author":"AS Baez","year":"2023","unstructured":"Baez AS, Ortiz-Whittingham LR, Tarfa H, Osei Baah F, Thompson K, Baumer Y, et al. Social determinants of health, health disparities, and adiposity. Prog Cardiovasc Dis. 2023;78:17\u201326. https:\/\/doi.org\/10.1016\/j.pcad.2023.04.011.","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"3352_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","volume":"130","author":"TM Powell-Wiley","year":"2022","unstructured":"Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, et al. Social determinants of cardiovascular disease. Circ Res. 2022;130(5):782\u201399. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319811.","journal-title":"Circ Res"},{"issue":"12","key":"3352_CR30","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41366-021-00937-9","volume":"45","author":"JH Buszkiewicz","year":"2021","unstructured":"Buszkiewicz JH, Bobb JF, Kapos F, Hurvitz PM, Arterburn D, Moudon AV, et al. Differential associations of the built environment on weight gain by sex and race\/ethnicity but not age. Int J Obes. 2021;45(12):2648\u201356. https:\/\/doi.org\/10.1038\/s41366-021-00937-9.","journal-title":"Int J Obes"},{"issue":"1","key":"3352_CR31","doi-asserted-by":"publisher","first-page":"23631","DOI":"10.1038\/s41598-024-74108-x","volume":"14","author":"M Rezaei","year":"2024","unstructured":"Rezaei M, Ghadamgahi F, Jayedi A, Arzhang P, Yekaninejad MS, Azadbakht L. The association between food insecurity and obesity, a body shape index and body roundness index among US adults. Sci Rep. 2024;14(1):23631. https:\/\/doi.org\/10.1038\/s41598-024-74108-x.","journal-title":"Sci Rep"},{"issue":"2","key":"3352_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/jci153357","volume":"132","author":"JM Valentine","year":"2022","unstructured":"Valentine JM, Ahmadian M, Keinan O, Abu-Odeh M, Zhao P, Zhou X, et al. \u03923-Adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity. J Clin Invest. 2022;132(2): e153357. https:\/\/doi.org\/10.1172\/jci153357.","journal-title":"J Clin Invest"},{"key":"3352_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbi.2014.07.014","volume":"43","author":"J Strahler","year":"2015","unstructured":"Strahler J, Rohleder N, Wolf JM. Acute psychosocial stress induces differential short-term changes in catecholamine sensitivity of stimulated inflammatory cytokine production. Brain Behav Immun. 2015;43:139\u201348. https:\/\/doi.org\/10.1016\/j.bbi.2014.07.014.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"3352_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/osp4.115","volume":"3","author":"JJ Lee","year":"2017","unstructured":"Lee JJ, Hwang SJ, Mutalik K, Corey D, Joyce R, Block JP, et al. Association of built environment characteristics with adiposity and glycaemic measures. Obes Sci Pract. 2017;3(3):333\u201341. https:\/\/doi.org\/10.1002\/osp4.115.","journal-title":"Obes Sci Pract"},{"issue":"6","key":"3352_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ncp.10885","volume":"37","author":"K Mauldin","year":"2022","unstructured":"Mauldin K, May M, Clifford D. The consequences of a weight-centric approach to healthcare: a case for a paradigm shift in how clinicians address body weight. Nutr Clin Pract. 2022;37(6):1291\u2013306. https:\/\/doi.org\/10.1002\/ncp.10885.","journal-title":"Nutr Clin Pract"},{"key":"3352_CR36","unstructured":"Velazquez A: Promoting a Weight-Inclusive Approach to Treat Obesity. https:\/\/www.medscape.com\/viewarticle\/promoting-weight-inclusive-approach-treat-obesity-2024a1000ff3 (2024). Accessed 05\/29\/2025."},{"issue":"10046","key":"3352_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","volume":"388","author":"E Di Angelantonio","year":"2016","unstructured":"Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(16)30175-1.","journal-title":"Lancet"},{"issue":"6","key":"3352_CR38","doi-asserted-by":"publisher","first-page":"e2415051","DOI":"10.1001\/jamanetworkopen.2024.15051","volume":"7","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ma N, Lin Q, Chen K, Zheng F, Wu J, et al. Body roundness index and all-cause mortality among US adults. JAMA Netw Open. 2024;7(6):e2415051. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15051.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"3352_CR39","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/jcm13082305","volume":"13","author":"MM Nowak","year":"2024","unstructured":"Nowak MM, Niemczyk M, Go\u0142\u0119biewski S, P\u0105czek L. Impact of body mass index on all-cause mortality in adults: a systematic review and meta-analysis. J Clin Med. 2024;13(8):2305. https:\/\/doi.org\/10.3390\/jcm13082305.","journal-title":"J Clin Med"},{"issue":"9","key":"3352_CR40","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41366-021-00860-z","volume":"45","author":"RM Puhl","year":"2021","unstructured":"Puhl RM, Lessard LM, Pearl RL, Himmelstein MS, Foster GD. International comparisons of weight stigma: addressing a void in the field. Int J Obes. 2021;45(9):1976\u201385. https:\/\/doi.org\/10.1038\/s41366-021-00860-z.","journal-title":"Int J Obes"},{"issue":"1","key":"3352_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13642","volume":"25","author":"S Nutter","year":"2024","unstructured":"Nutter S, Eggerichs LA, Nagpal TS, Ramos Salas X, Chin Chea C, Saiful S, et al. Changing the global obesity narrative to recognize and reduce weight stigma: A position statement from the World Obesity Federation. Obes Rev. 2024;25(1): e13642. https:\/\/doi.org\/10.1111\/obr.13642.","journal-title":"Obes Rev"},{"issue":"1","key":"3352_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12160-016-9831-7","volume":"51","author":"M Vadiveloo","year":"2017","unstructured":"Vadiveloo M, Mattei J. Perceived weight discrimination and 10-year risk of allostatic load among US adults. Ann Behav Med. 2017;51(1):94\u2013104. https:\/\/doi.org\/10.1007\/s12160-016-9831-7.","journal-title":"Ann Behav Med"},{"issue":"11","key":"3352_CR43","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1177\/0956797615601103","volume":"26","author":"AR Sutin","year":"2015","unstructured":"Sutin AR, Stephan Y, Terracciano A. Weight discrimination and risk of mortality. Psychol Sci. 2015;26(11):1803\u201311. https:\/\/doi.org\/10.1177\/0956797615601103.","journal-title":"Psychol Sci"},{"issue":"4","key":"3352_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41591-020-0803-x","volume":"26","author":"F Rubino","year":"2020","unstructured":"Rubino F, Puhl RM, Cummings DE, Eckel RH, Ryan DH, Mechanick JI, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0803-x.","journal-title":"Nat Med"},{"issue":"10077","key":"3352_CR45","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7.","journal-title":"Lancet"},{"issue":"12","key":"3352_CR46","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/oby.21657","volume":"24","author":"SE Jackson","year":"2016","unstructured":"Jackson SE, Kirschbaum C, Steptoe A. Perceived weight discrimination and chronic biochemical stress: a population-based study using cortisol in scalp hair. Endocrinol Metab Clin North Am. 2016;24(12):2515\u201321. https:\/\/doi.org\/10.1002\/oby.21657.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"3352_CR47","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1172\/JCI129191","volume":"129","author":"L Vishvanath","year":"2019","unstructured":"Vishvanath L, Gupta RK. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J Clin Invest. 2019;129(10):4022\u201331. https:\/\/doi.org\/10.1172\/JCI129191.","journal-title":"J Clin Invest"},{"issue":"11","key":"3352_CR48","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","volume":"126","author":"M-E Pich\u00e9","year":"2020","unstructured":"Pich\u00e9 M-E, Tchernof A, Despr\u00e9s J-P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477\u2013500. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316101.","journal-title":"Circ Res"},{"issue":"1","key":"3352_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof A, Despr\u00e9s J-P. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359\u2013404. https:\/\/doi.org\/10.1152\/physrev.00033.2011.","journal-title":"Physiol Rev"},{"issue":"7121","key":"3352_CR50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"J-P Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881\u20137. https:\/\/doi.org\/10.1038\/nature05488.","journal-title":"Nature"},{"issue":"6","key":"3352_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/ATVBAHA.107.159228","volume":"28","author":"J-P Despr\u00e9s","year":"2008","unstructured":"Despr\u00e9s J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28(6):1039\u201349. https:\/\/doi.org\/10.1161\/ATVBAHA.107.159228.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"3352_CR52","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","volume":"126","author":"J-P Despr\u00e9s","year":"2012","unstructured":"Despr\u00e9s J-P. Body fat distribution and risk of cardiovascular disease. Circulation. 2012;126(10):1301\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.067264.","journal-title":"Circulation"},{"issue":"6","key":"3352_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/eurheartj\/ehp487","volume":"31","author":"A Romero-Corral","year":"2010","unstructured":"Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehp487.","journal-title":"Eur Heart J"},{"issue":"11","key":"3352_CR54","doi-asserted-by":"publisher","first-page":"827","DOI":"10.7326\/M14-2525","volume":"163","author":"KR Sahakyan","year":"2015","unstructured":"Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163(11):827\u201335. https:\/\/doi.org\/10.7326\/M14-2525.","journal-title":"Ann Intern Med"},{"key":"3352_CR55","doi-asserted-by":"publisher","unstructured":"Coutinho T, Goel K, Corr\u00eaa de S\u00e1 D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of \u201cnormal weight central obesity\u201d. J Am College Cardiol 2013;61(5):553\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.035.","DOI":"10.1016\/j.jacc.2012.10.035"},{"issue":"5","key":"3352_CR56","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/2047487313492631","volume":"20","author":"D Canoy","year":"2013","unstructured":"Canoy D, Cairns BJ, Balkwill A, Wright FL, Green J, Reeves G, et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index. Eur J Prev Cardiol. 2013;20(5):759\u201362. https:\/\/doi.org\/10.1177\/2047487313492631.","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"3352_CR57","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1161\/CIRCULATIONAHA.107.739714","volume":"117","author":"C Zhang","year":"2008","unstructured":"Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality. Circulation. 2008;117(13):1658\u201367. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.739714.","journal-title":"Circulation"},{"issue":"8","key":"3352_CR58","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/14779072.2017.1352471","volume":"15","author":"M Rodriguez Flores","year":"2017","unstructured":"Rodriguez Flores M, Aguilar Salinas C, Pich\u00e9 M-E, Auclair A, Poirier P. Effect of bariatric surgery on heart failure. Expert Rev Cardiovasc Ther. 2017;15(8):567\u201379. https:\/\/doi.org\/10.1080\/14779072.2017.1352471.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"3352_CR59","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/CIRCIMAGING.113.000532","volume":"6","author":"IJ Neeland","year":"2013","unstructured":"Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013;6(5):800\u20137. https:\/\/doi.org\/10.1161\/CIRCIMAGING.113.000532.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"3352_CR60","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/hr.2011.157","volume":"35","author":"T Murase","year":"2012","unstructured":"Murase T, Hattori T, Ohtake M, Abe M, Amakusa Y, Takatsu M, et al. Cardiac remodeling and diastolic dysfunction in DahlS.Z-Leprfa\/Leprfa rats: a new animal model of metabolic syndrome. Hypertens Res. 2012;35(2):186\u201393. https:\/\/doi.org\/10.1038\/hr.2011.157.","journal-title":"Hypertens Res"},{"issue":"7","key":"3352_CR61","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.115.016801","volume":"133","author":"D Aune","year":"2016","unstructured":"Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality. Circulation. 2016;133(7):639\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016801.","journal-title":"Circulation"},{"issue":"6","key":"3352_CR62","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jcmg.2017.04.001","volume":"10","author":"W Kosmala","year":"2017","unstructured":"Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in metabolic diseases. JACC Cardiovasc Imaging. 2017;10(6):692\u2013703. https:\/\/doi.org\/10.1016\/j.jcmg.2017.04.001.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"3352_CR63","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","volume":"70","author":"CJ Lavie","year":"2017","unstructured":"Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017;70(16):2022\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.002.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"3352_CR64","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","volume":"292","author":"TJ Wang","year":"2004","unstructured":"Wang TJ. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292(20):2471. https:\/\/doi.org\/10.1001\/jama.292.20.2471.","journal-title":"JAMA"},{"issue":"2","key":"3352_CR65","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ahj.2007.10.004","volume":"155","author":"N Wanahita","year":"2008","unstructured":"Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity\u2014results of a meta-analysis. Am Heart J. 2008;155(2):310\u20135. https:\/\/doi.org\/10.1016\/j.ahj.2007.10.004.","journal-title":"Am Heart J"},{"issue":"3","key":"3352_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/heartjnl-2014-306238","volume":"101","author":"S Adabag","year":"2015","unstructured":"Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, et al. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart. 2015;101(3):215. https:\/\/doi.org\/10.1136\/heartjnl-2014-306238.","journal-title":"Heart"},{"issue":"9","key":"3352_CR67","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1586\/14779072.2014.952283","volume":"12","author":"B Plourde","year":"2014","unstructured":"Plourde B, Sarrazin J-F, Nault I, Poirier P. Sudden cardiac death and obesity. Expert Rev Cardiovasc Ther. 2014;12(9):1099\u2013110. https:\/\/doi.org\/10.1586\/14779072.2014.952283.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10","key":"3352_CR68","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1001\/archinte.1987.00370100039008","volume":"147","author":"FH Messerli","year":"1987","unstructured":"Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death: increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med. 1987;147(10):1725\u20138. https:\/\/doi.org\/10.1001\/archinte.1987.00370100039008.","journal-title":"Arch Intern Med"},{"issue":"4","key":"3352_CR69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1467-789x.2005.00199.x","volume":"6","author":"MA Fraley","year":"2005","unstructured":"Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev. 2005;6(4):275\u201381. https:\/\/doi.org\/10.1111\/j.1467-789x.2005.00199.x.","journal-title":"Obes Rev"},{"issue":"10","key":"3352_CR70","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.hrthm.2011.06.031","volume":"8","author":"E Hookana","year":"2011","unstructured":"Hookana E, Junttila MJ, Puurunen V-P, Tikkanen JT, Kaikkonen KS, Kortelainen M-L, et al. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8(10):1570\u20135. https:\/\/doi.org\/10.1016\/j.hrthm.2011.06.031.","journal-title":"Heart Rhythm"},{"issue":"5","key":"3352_CR71","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.106.131755","volume":"27","author":"G Fantuzzi","year":"2007","unstructured":"Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(5):996\u20131003. https:\/\/doi.org\/10.1161\/ATVBAHA.106.131755.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3352_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/ceh.2023.130744","volume":"9","author":"AE Platek","year":"2023","unstructured":"Platek AE, Szymanska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Experim Hepatol. 2023;9(3):187\u201392. https:\/\/doi.org\/10.5114\/ceh.2023.130744.","journal-title":"Clin Experim Hepatol"},{"key":"3352_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136247","author":"J Zbrze\u017aniak-Suszczewicz","year":"2025","unstructured":"Zbrze\u017aniak-Suszczewicz J, Winiarska A, Perkowska-Ptasi\u0144ska A, Stomp\u00f3r T. Obesity-related glomerulosclerosis\u2014how adiposity damages the kidneys. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26136247.","journal-title":"Int J Mol Sci"},{"key":"3352_CR74","unstructured":"Centers for Disease Control and Prevention: National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States. https:\/\/stacks.cdc.gov\/view\/cdc\/85309\/cdc_85309_DS1.pdf (2020). Accessed 05\/29\/2025."},{"key":"3352_CR75","unstructured":"Pavkov ME, Miyamot Y. Diabetes and Kidney Disease. International Diabetes Federation Atlas Reports: Chronic Kidney Disease Initiative, Division of Diabetes Translation, at the Centers for Disease Control and Prevention; 2023."},{"issue":"2","key":"3352_CR76","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77\u201382. https:\/\/doi.org\/10.2337\/diaclin.26.2.77.","journal-title":"Clin Diabetes"},{"issue":"9","key":"3352_CR77","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMc1602469","volume":"375","author":"L Zhang","year":"2016","unstructured":"Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905\u20136. https:\/\/doi.org\/10.1056\/NEJMc1602469.","journal-title":"N Engl J Med"},{"issue":"1","key":"3352_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","unstructured":"GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362.","journal-title":"N Engl J Med"},{"issue":"2","key":"3352_CR79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/cancers15020485","volume":"15","author":"S Pati","year":"2023","unstructured":"Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers. 2023;15(2):485. https:\/\/doi.org\/10.3390\/cancers15020485.","journal-title":"Cancers"},{"key":"3352_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101429","volume":"48","author":"ZJ Ward","year":"2022","unstructured":"Ward ZJ, Willett WC, Hu FB, Pacheco LS, Long MW, Gortmaker SL. Excess mortality associated with elevated body weight in the USA by state and demographic subgroup: a modelling study. eClin Med. 2022;48: 101429. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101429.","journal-title":"eClin Med"},{"issue":"18","key":"3352_CR81","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028409","volume":"12","author":"Z Raisi-Estabragh","year":"2023","unstructured":"Raisi-Estabragh Z, Kobo O, Mieres JH, Bullock-Palmer RP, Van Spall HGC, Breathett K, et al. Racial disparities in obesity-related cardiovascular mortality in the United States: temporal trends from 1999 to 2020. J Am Heart Assoc. 2023;12(18): e028409. https:\/\/doi.org\/10.1161\/JAHA.122.028409.","journal-title":"J Am Heart Assoc"},{"key":"3352_CR82","unstructured":"Montero A, Sparks G, Kirzinger A, Valdes I, Hamel L. KFF Health Tracking Poll July 2023: The Public\u2019s Views Of New Prescription Weight Loss Drugs And Prescription Drug Costs. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-july-2023-the-publics-views-of-new-prescription-weight-loss-drugs-and-prescription-drug-costs\/ (2023). Accessed 05\/29\/2025."},{"issue":"6","key":"3352_CR83","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.soard.2015.11.027","volume":"12","author":"JB Dixon","year":"2016","unstructured":"Dixon JB. Regional differences in the coverage and uptake of bariatric\u2013metabolic surgery: a focus on type 2 diabetes. Surg Obes Relat Dis. 2016;12(6):1171\u20137. https:\/\/doi.org\/10.1016\/j.soard.2015.11.027.","journal-title":"Surg Obes Relat Dis"},{"key":"3352_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102879","volume":"46","author":"R Szymanski","year":"2024","unstructured":"Szymanski R, Abraham M, Childs W, Le K, Velez C, Vaughn I, et al. Factors associated with receiving an obesity diagnosis and obesity-related treatment for patients with obesity class II and III within a single integrated health system. Prev Med Rep. 2024;46: 102879. https:\/\/doi.org\/10.1016\/j.pmedr.2024.102879.","journal-title":"Prev Med Rep"},{"issue":"20","key":"3352_CR85","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897.","journal-title":"JAMA"},{"issue":"2","key":"3352_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187\u201394. https:\/\/doi.org\/10.1007\/s13679-017-0262-y.","journal-title":"Curr Obes Rep"},{"issue":"2","key":"3352_CR87","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342\u201362. https:\/\/doi.org\/10.1210\/jc.2014-3415.","journal-title":"J Clin Endocrinol Metab"},{"key":"3352_CR88","unstructured":"Beverly T, Aras M, Kumar R, Aronne L. Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR AS, Anawalt B, editor. Endotext. South Dartmouth (MA): MDText.com, Inc.: MDText.com, Inc.; 2024."},{"key":"3352_CR89","unstructured":"American Society for Metabolic and Bariatric Surgery: After 30 Years \u2014 New Guidelines for Weight-Loss Surgery. https:\/\/asmbs.org\/news_releases\/after-30-years-new-guidelines-for-weight-loss-surgery\/ (2022). Accessed 05\/29\/2025."},{"issue":"5","key":"3352_CR90","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC202405210","volume":"177","author":"AH Gilden","year":"2024","unstructured":"Gilden AH, Catenacci VA, Taormina JM. Obesity. Ann Intern Med. 2024;177(5):ITC65\u201380. https:\/\/doi.org\/10.7326\/AITC202405210.","journal-title":"Ann Intern Med"},{"issue":"12","key":"3352_CR91","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","volume":"25","author":"The Diabetes Prevention Program Research Group","year":"2002","unstructured":"The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165\u201371. https:\/\/doi.org\/10.2337\/diacare.25.12.2165.","journal-title":"Diabetes Care"},{"issue":"5","key":"3352_CR92","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/oby.2006.84","volume":"14","author":"The Look Ahead Research Group","year":"2006","unstructured":"The Look Ahead Research Group. The look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737\u201352. https:\/\/doi.org\/10.1038\/oby.2006.84.","journal-title":"Obesity"},{"issue":"10","key":"3352_CR93","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2337\/dc16-2099","volume":"40","author":"EK Ely","year":"2017","unstructured":"Ely EK, Gruss SM, Luman ET, Gregg EW, Ali MK, Nhim K, et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC\u2019s national diabetes prevention program. Diabetes Care. 2017;40(10):1331\u201341. https:\/\/doi.org\/10.2337\/dc16-2099.","journal-title":"Diabetes Care"},{"issue":"10","key":"3352_CR94","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/oby.22594","volume":"27","author":"TA Wadden","year":"2019","unstructured":"Wadden TA, Tsai AG, Tronieri JS. A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL-IBT program. Endocrinol Metab Clin North Am. 2019;27(10):1562\u20136. https:\/\/doi.org\/10.1002\/oby.22594.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"3352_CR95","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2024.10816","volume":"332","author":"KA Gudzune","year":"2024","unstructured":"Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024;332(7):571\u201384. https:\/\/doi.org\/10.1001\/jama.2024.10816.","journal-title":"JAMA"},{"issue":"11","key":"3352_CR96","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Endocrinol Metab Clin North Am. 2013;21(11):2163\u201371. https:\/\/doi.org\/10.1002\/oby.20584.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9774","key":"3352_CR97","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(11)60205-5.","journal-title":"Lancet"},{"issue":"2","key":"3352_CR98","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308. https:\/\/doi.org\/10.3945\/ajcn.111.024927.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"3352_CR99","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Endocrinol Metab Clin North Am. 2012;20(2):330\u201342. https:\/\/doi.org\/10.1038\/oby.2011.330.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"3352_CR100","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Endocrinol Metab Clin North Am. 2013;21(5):935\u201343. https:\/\/doi.org\/10.1002\/oby.20309.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9741","key":"3352_CR101","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(10)60888-4.","journal-title":"Lancet"},{"issue":"10","key":"3352_CR102","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone\u2013bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990\u20131004. https:\/\/doi.org\/10.1001\/jama.2016.1558.","journal-title":"JAMA"},{"issue":"1","key":"3352_CR103","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6Str\u00f6M L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27(1):155\u201361. https:\/\/doi.org\/10.2337\/diacare.27.1.155.","journal-title":"Diabetes Care"},{"issue":"15","key":"3352_CR104","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.37765\/ajmc.2022.89292","volume":"28","author":"M-A Cornier","year":"2022","unstructured":"Cornier M-A. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15):S288\u201396. https:\/\/doi.org\/10.37765\/ajmc.2022.89292.","journal-title":"Am J Manag Care"},{"issue":"1","key":"3352_CR105","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3352_CR106","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"11","key":"3352_CR107","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443\u201351. https:\/\/doi.org\/10.1038\/ijo.2013.120.","journal-title":"Int J Obes"},{"issue":"3","key":"3352_CR108","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Endocrinol Metab Clin North Am. 2020;28(3):529\u201336. https:\/\/doi.org\/10.1002\/oby.22726.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"3352_CR109","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399. https:\/\/doi.org\/10.1001\/jama.2015.9676.","journal-title":"JAMA"},{"issue":"11","key":"3352_CR110","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"PH Wilding John","year":"2021","unstructured":"Wilding John PH, Batterham Rachel L, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"10278","key":"3352_CR111","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"issue":"14","key":"3352_CR112","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"issue":"10","key":"3352_CR113","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"3","key":"3352_CR114","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3352_CR115","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, et al. Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395. https:\/\/doi.org\/10.1016\/S2213-8587(23)00388-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3352_CR116","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"issue":"14","key":"3352_CR117","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"issue":"6","key":"3352_CR118","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"Iqbal J, Wu H-X, Hu N, Zhou Y-H, Li L, Xiao F, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022;23(6): e13435. https:\/\/doi.org\/10.1111\/obr.13435.","journal-title":"Obes Rev"},{"issue":"3","key":"3352_CR119","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"1","key":"3352_CR120","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"issue":"10402","key":"3352_CR121","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet"},{"issue":"11","key":"3352_CR122","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"12","key":"3352_CR123","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1007\/s11695-024-07510-z","volume":"34","author":"BKA Dayyeh","year":"2024","unstructured":"Dayyeh BKA, Stier C, Alqahtani A, Sharaiha R, Bandhari M, Perretta S, et al. IFSO bariatric endoscopy committee evidence-based review and position statement on endoscopic sleeve gastroplasty for obesity management. Obes Surg. 2024;34(12):4318\u201348.","journal-title":"Obes Surg"},{"issue":"4","key":"3352_CR124","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.gtc.2024.08.017","volume":"53","author":"RH Matar","year":"2024","unstructured":"Matar RH, Abu Dayyeh BK. Advances in endoscopic bariatric and metabolic therapies. Gastroenterol Clin North Am. 2024;53(4):731\u201345. https:\/\/doi.org\/10.1016\/j.gtc.2024.08.017.","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"3352_CR125","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11938-023-00420-6","volume":"21","author":"N Dave","year":"2023","unstructured":"Dave N, Dawod E, Simmons OL. Endobariatrics: a still underutilized weight loss tool. Curr Treat Options Gastroenterol. 2023;21(2):172\u201384.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"2","key":"3352_CR126","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11695-021-05772-5","volume":"32","author":"JH Loo","year":"2022","unstructured":"Loo JH, Lim YH, Seah HL, Chong AZQ, Tay KV. Intragastric balloon as bridging therapy prior to bariatric surgery for patients with severe obesity (BMI \u2265 50 kg\/m2): a systematic review and meta-analysis. Obes Surg. 2022;32(2):489\u2013502. https:\/\/doi.org\/10.1007\/s11695-021-05772-5.","journal-title":"Obes Surg"},{"key":"3352_CR127","doi-asserted-by":"publisher","unstructured":"Jense MTF, Hodde T, Palm-Meinders IH, Bours PHA, Soufidi K, Boerma E-JG, et al. The POSE-2 procedure for people with obesity: a safe and effective treatment option. Obesity Surg 2024;34(10):3686\u201393. https:\/\/doi.org\/10.1007\/s11695-024-07488-8.","DOI":"10.1007\/s11695-024-07488-8"},{"issue":"2","key":"3352_CR128","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/oby.21702","volume":"25","author":"S Sullivan","year":"2017","unstructured":"Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Mu\u00f1oz N, Jonnalagadda SS, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Endocrinol Metab Clin North Am. 2017;25(2):294\u2013301. https:\/\/doi.org\/10.1002\/oby.21702.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"3352_CR129","doi-asserted-by":"publisher","first-page":"E1349","DOI":"10.1055\/a-1221-9835","volume":"8","author":"E Espinet-Coll","year":"2020","unstructured":"Espinet-Coll E, Nebreda-Dur\u00e1n J, Galvao-Neto M, Bautista-Altamirano C, Diaz-Gal\u00e1n P, G\u00f3mez-Valero JA, et al. Suture pattern does not influence outcomes of endoscopic sleeve gastroplasty in obese patients. Endosc Int Open. 2020;8(10):E1349\u201358. https:\/\/doi.org\/10.1055\/a-1221-9835.","journal-title":"Endosc Int Open"},{"issue":"2","key":"3352_CR130","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gutjnl-2019-318349","volume":"69","author":"ACG van Baar","year":"2020","unstructured":"van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295\u2013303. https:\/\/doi.org\/10.1136\/gutjnl-2019-318349.","journal-title":"Gut"},{"key":"3352_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071027","author":"AP Courcoulas","year":"2023","unstructured":"Courcoulas AP, Daigle CR, Arterburn DE. Long term outcomes of metabolic\/bariatric surgery in adults. BMJ. 2023. https:\/\/doi.org\/10.1136\/bmj-2022-071027.","journal-title":"BMJ"},{"key":"3352_CR132","unstructured":"American Society for Metabolic and Bariatric Surgery: Access to Care Fact Sheet. https:\/\/asmbs.org\/resources\/access-to-care-fact-sheet\/ (2022). Accessed August 3 2025."},{"issue":"10382","key":"3352_CR133","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","volume":"401","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)02403-5.","journal-title":"Lancet"},{"issue":"4","key":"3352_CR134","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.gtc.2023.08.002","volume":"52","author":"K Alabduljabbar","year":"2023","unstructured":"Alabduljabbar K, Bonanos E, Miras AD, le Roux CW. Mechanisms of action of bariatric surgery on body weight regulation. Gastroenterol Clin North Am. 2023;52(4):691\u2013705. https:\/\/doi.org\/10.1016\/j.gtc.2023.08.002.","journal-title":"Gastroenterol Clin North Am"},{"key":"3352_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101517","volume":"68","author":"VL Albaugh","year":"2023","unstructured":"Albaugh VL, He Y, M\u00fcnzberg H, Morrison CD, Yu S, Berthoud H-R. Regulation of body weight: lessons learned from bariatric surgery. Mol Metab. 2023;68: 101517.","journal-title":"Mol Metab"},{"issue":"1","key":"3352_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/tsaco-2018-000219","volume":"3","author":"R Lim","year":"2018","unstructured":"Lim R, Beekley A, Johnson DC, Davis KA. Early and late complications of bariatric operation. Trauma Surg Acute Care Open. 2018;3(1): e000219.","journal-title":"Trauma Surg Acute Care Open"},{"key":"3352_CR137","doi-asserted-by":"publisher","unstructured":"Monteiro Delgado L, Fabretina de Souza V, Fontel Pompeu B, de Moraes Ogawa T, Pereira Oliveira H, Sacksida Vallad\u00e3o VdC, et al. Long-term outcomes in sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of randomized trials. Obesity Surg 2025. https:\/\/doi.org\/10.1007\/s11695-025-08044-8.","DOI":"10.1007\/s11695-025-08044-8"},{"issue":"8","key":"3352_CR138","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamasurg.2022.2229","volume":"157","author":"P Salminen","year":"2022","unstructured":"Salminen P, Gr\u00f6nroos S, Helmi\u00f6 M, Hurme S, Juuti A, Juusela R, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2022;157(8):656\u201366. https:\/\/doi.org\/10.1001\/jamasurg.2022.2229.","journal-title":"JAMA Surg"},{"issue":"3","key":"3352_CR139","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41366-024-01461-2","volume":"49","author":"N \u00c7al\u0131k Ba\u015faran","year":"2024","unstructured":"\u00c7al\u0131k Ba\u015faran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. Int J Obes. 2024;49(3):412\u20137. https:\/\/doi.org\/10.1038\/s41366-024-01461-2.","journal-title":"Int J Obes"},{"issue":"4","key":"3352_CR140","doi-asserted-by":"publisher","first-page":"e246221","DOI":"10.1001\/jamanetworkopen.2024.6221","volume":"7","author":"M Haseeb","year":"2024","unstructured":"Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide vs endoscopic sleeve gastroplasty for weight loss. JAMA Netw Open. 2024;7(4):e246221. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.6221.","journal-title":"JAMA Netw Open"},{"key":"3352_CR141","doi-asserted-by":"publisher","unstructured":"Marso Steven P, Daniels Gilbert H, Brown-Frandsen K, Kristensen P, Mann Johannes FE, Nauck Michael A, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med 375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","DOI":"10.1056\/NEJMoa1603827"},{"issue":"1","key":"3352_CR142","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"3352_CR143","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"5","key":"3352_CR144","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"5","key":"3352_CR145","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"12","key":"3352_CR146","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"2","key":"3352_CR147","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","volume":"25","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468\u201378. https:\/\/doi.org\/10.1111\/dom.14890.","journal-title":"Diabetes Obes Metab"},{"key":"3352_CR148","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yjmcc.2015.09.018","volume":"89","author":"M Wallner","year":"2015","unstructured":"Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, et al. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol. 2015;89:365\u201375. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.09.018.","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"3352_CR149","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, et al. GLP-1 receptor expression within the human heart. Endocrinology. 2018;159(4):1570\u201384. https:\/\/doi.org\/10.1210\/en.2018-00004.","journal-title":"Endocrinology"},{"issue":"4","key":"3352_CR150","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db13-1440","volume":"63","author":"P Richards","year":"2014","unstructured":"Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014;63(4):1224\u201333. https:\/\/doi.org\/10.2337\/db13-1440.","journal-title":"Diabetes"},{"issue":"8","key":"3352_CR151","doi-asserted-by":"publisher","first-page":"F867","DOI":"10.1152\/ajprenal.00527.2014","volume":"308","author":"EP Jensen","year":"2015","unstructured":"Jensen EP, Poulsen SS, Kissow H, Holstein-Rathlou N-H, Deacon CF, Jensen BL, et al. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Renal Physiol. 2015;308(8):F867\u201377. https:\/\/doi.org\/10.1152\/ajprenal.00527.2014.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"3352_CR152","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15\u201330. https:\/\/doi.org\/10.1016\/j.cmet.2016.06.009.","journal-title":"Cell Metab"},{"issue":"15","key":"3352_CR153","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"issue":"11","key":"3352_CR154","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000561","volume":"8","author":"EL Jensen","year":"2024","unstructured":"Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists. Hepatol Commun. 2024;8(11): e0561. https:\/\/doi.org\/10.1097\/HC9.0000000000000561.","journal-title":"Hepatol Commun"},{"issue":"2","key":"3352_CR155","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cmet.2023.12.018","volume":"36","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 2024;36(2):338\u201353. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.018.","journal-title":"Cell Metab"},{"issue":"2","key":"3352_CR156","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","volume":"41","author":"JH Yu","year":"2022","unstructured":"Yu JH, Park SY, Lee DY, Kim NH, Seo JA. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin Pract. 2022;41(2):136\u201349. https:\/\/doi.org\/10.23876\/j.krcp.22.001.","journal-title":"Kidney Res Clin Pract"},{"issue":"2","key":"3352_CR157","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"9","key":"3352_CR158","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011.","journal-title":"N Engl J Med"},{"issue":"6","key":"3352_CR159","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/dom.15524","volume":"26","author":"MF Abdelmalek","year":"2024","unstructured":"Abdelmalek MF, Harrison SA, Sanyal AJ. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metab. 2024;26(6):2001\u201316. https:\/\/doi.org\/10.1111\/dom.15524.","journal-title":"Diabetes Obes Metab"},{"issue":"10019","key":"3352_CR160","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"issue":"4","key":"3352_CR161","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"12","key":"3352_CR162","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"3352_CR163","unstructured":"Novo Nordisk: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial. https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/395f870c-3f29-49e2-a8f5-b469ae261625 (2024). Accessed 05\/29\/2025."},{"issue":"3","key":"3352_CR164","doi-asserted-by":"publisher","first-page":"G329","DOI":"10.1152\/ajpgi.00044.2018","volume":"315","author":"S Hohenester","year":"2018","unstructured":"Hohenester S, Christiansen S, Nagel J, Wimmer R, Artmann R, Denk G, et al. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G329\u201338. https:\/\/doi.org\/10.1152\/ajpgi.00044.2018.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"3352_CR165","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"A-S Alexopoulos","year":"2021","unstructured":"Alexopoulos A-S, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology. 2021;74(3):1220\u201333. https:\/\/doi.org\/10.1002\/hep.31806.","journal-title":"Hepatology"},{"issue":"1","key":"3352_CR166","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1186\/s12889-022-13176-y","volume":"22","author":"E van den Broek-Altenburg","year":"2022","unstructured":"van den Broek-Altenburg E, Atherly A, Holladay E. Changes in healthcare spending attributable to obesity and overweight: payer- and service-specific estimates. BMC Public Health. 2022;22(1):962. https:\/\/doi.org\/10.1186\/s12889-022-13176-y.","journal-title":"BMC Public Health"},{"issue":"4","key":"3352_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.70000","volume":"10","author":"K Ferreira","year":"2024","unstructured":"Ferreira K, Kont E, Abdelkhalik A, Jones D, Baker-Knight J. The out-of-pocket cost of living with obesity: results from a survey in Spain, South Korea, Brazil, India, Italy, and Japan. Obes Sci Pract. 2024;10(4): e70000. https:\/\/doi.org\/10.1002\/osp4.70000.","journal-title":"Obes Sci Pract"},{"issue":"1","key":"3352_CR168","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1186\/s12889-023-16855-6","volume":"23","author":"S Zhao","year":"2023","unstructured":"Zhao S, Xu X, You H, Ge J, Wu Q. Healthcare costs attributable to abnormal weight in China: evidence based on a longitudinal study. BMC Public Health. 2023;23(1):1927. https:\/\/doi.org\/10.1186\/s12889-023-16855-6.","journal-title":"BMC Public Health"},{"issue":"7","key":"3352_CR169","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/s2213-8587(21)00118-2","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhao L, Gao L, Pan A, Xue H. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol. 2021;9(7):446\u201361. https:\/\/doi.org\/10.1016\/s2213-8587(21)00118-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3352_CR170","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(21)00047-4","volume":"9","author":"Q Zeng","year":"2021","unstructured":"Zeng Q, Li N, Pan X-F, Chen L, Pan A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):393\u2013405. https:\/\/doi.org\/10.1016\/S2213-8587(21)00047-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3352_CR171","unstructured":"Liu J, Yao J, Tao F, Jiang H, Li J, Pang S, et al. Efficacy and safety of tirzepatide once weekly in Chinese participants without Type 2 Diabetes who have obesity or are overweight with weight-related comorbidities: a randomized, double-blind, placebo-controlled trial (SURMOUNT-CN). https:\/\/www.medifind.com\/articles\/clinical-trial\/313390877 (2022). Accessed 05\/29\/2025."},{"issue":"12","key":"3352_CR172","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.2024.2252","volume":"331","author":"D Mozaffarian","year":"2024","unstructured":"Mozaffarian D. GLP-1 agonists for obesity\u2014a new recipe for success? JAMA. 2024;331(12):1007\u20138. https:\/\/doi.org\/10.1001\/jama.2024.2252.","journal-title":"JAMA"},{"issue":"8050","key":"3352_CR173","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41586-025-00404-9","volume":"638","author":"E Dolgin","year":"2025","unstructured":"Dolgin E. Dozens of new obesity drugs are coming: these are the ones to watch. Nature. 2025;638(8050):308\u201310. https:\/\/doi.org\/10.1038\/d41586-025-00404-9.","journal-title":"Nature"},{"issue":"1","key":"3352_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00944-2","volume":"30","author":"R-l Li","year":"2024","unstructured":"Li R-l, Kang S. Rewriting cellular fate: epigenetic interventions in obesity and cellular programming. Mol Med. 2024;30(1): 169. https:\/\/doi.org\/10.1186\/s10020-024-00944-2.","journal-title":"Mol Med"},{"issue":"19","key":"3352_CR175","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038088","volume":"103","author":"OP Ugwu","year":"2024","unstructured":"Ugwu OP, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 2024;103(19): e38088. https:\/\/doi.org\/10.1097\/md.0000000000038088.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3352_CR176","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s13679-024-00576-x","volume":"13","author":"S Sherf-Dagan","year":"2024","unstructured":"Sherf-Dagan S, Refaeli R, Buch A. Phenotyping of obesity treatment candidates: a narrative review. Curr Obes Rep. 2024;13(3):564\u201373. https:\/\/doi.org\/10.1007\/s13679-024-00576-x.","journal-title":"Curr Obes Rep"},{"key":"3352_CR177","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Q, Xue M, Pang B, Yang M, Zhang Z, et al. Identifying factors associated with central obesity in school students using artificial intelligence techniques. Front Pediat. 2022;10.","DOI":"10.3389\/fped.2022.1060270"},{"issue":"3","key":"3352_CR178","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003051","volume":"17","author":"EW Yu","year":"2020","unstructured":"Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Torres Soto M, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3): e1003051. https:\/\/doi.org\/10.1371\/journal.pmed.1003051.","journal-title":"PLoS Med"},{"issue":"7","key":"3352_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/life13071488","volume":"13","author":"D Hu","year":"2023","unstructured":"Hu D, Zhao J, Zhang H, Wang G, Gu Z. Fecal microbiota transplantation for weight and glycemic control of obesity as well as the associated metabolic diseases: meta-analysis and comprehensive assessment. Life. 2023;13(7): 1488. https:\/\/doi.org\/10.3390\/life13071488.","journal-title":"Life"},{"issue":"2","key":"3352_CR180","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/joe-13-0284","volume":"220","author":"K Fosgerau","year":"2014","unstructured":"Fosgerau K, Raun K, Nilsson C, Dahl K, Wulff BS. Novel \u03b1-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity. J Endocrinol. 2014;220(2):97\u2013107. https:\/\/doi.org\/10.1530\/joe-13-0284.","journal-title":"J Endocrinol"},{"issue":"5","key":"3352_CR181","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41573-024-01125-w","volume":"24","author":"G Chen","year":"2025","unstructured":"Chen G, Chen L, Li X, Mohammadi M. FGF-based drug discovery: advances and challenges. Nat Rev Drug Discov. 2025;24(5):335\u201357. https:\/\/doi.org\/10.1038\/s41573-024-01125-w.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"3352_CR182","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","volume":"5","author":"A Liskiewicz","year":"2023","unstructured":"Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5(12):2075\u201385. https:\/\/doi.org\/10.1038\/s42255-023-00931-7.","journal-title":"Nat Metab"},{"issue":"3","key":"3352_CR183","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes. 2025;49(3):433\u201351.","journal-title":"Int J Obes"},{"issue":"21","key":"3352_CR184","doi-asserted-by":"publisher","first-page":"2310351","DOI":"10.1002\/adma.202310351","volume":"36","author":"C-H Mac","year":"2024","unstructured":"Mac C-H, Tai H-M, Huang S-M, Peng H-H, Sharma AK, Nguyen GLT, et al. Orally ingested self-powered stimulators for targeted gut-brain axis electrostimulation to treat obesity and metabolic disorders. Adv Mater. 2024;36(21):2310351. https:\/\/doi.org\/10.1002\/adma.202310351.","journal-title":"Adv Mater"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03352-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:42Z","timestamp":1762030962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":184,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3352"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03352-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amanda Velazquez: Advisory board\u2014Eli Lilly (current), Intellihealth, Consultant\u2014novo Nordisk (current), Advisory board: weight watchers (previous). All other authors (Vidhi Singh, Jia Sun, Susan Cheng, Alan C. Kwan) report no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}